Imara announces launch of proposed public offering

Boston, july 13, 2021 (globe newswire) -- imara inc. (the “company”) (nasdaq: imra), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it has commenced a proposed underwritten public offering of $50 million of shares of its common stock. all of the shares are being offered by the company. the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. in addition, the company intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock.
ELVN Ratings Summary
ELVN Quant Ranking